Zentalis (ZNTL) Pharmaceuticals provided a corporate update and highlighted key milestones and expected momentum in the azenosertib development program for 2026. 2025 Accomplishments: Completed enrollment in DENALI Part 2a, supporting registration-intended development of azenosertib; Aligned with the FDA on confirmatory ASPENOVA Phase 3 trial design; Strong data across three trials in PROC established a solid foundation for the lead indication in Cyclin E1-positive platinum-resistant ovarian cancer; Maintained a strong cash position supporting an estimated runway into late 2027 following strategic restructuring to focus pipeline and resources. Anticipated 2026 Milestones: DENALI Part 2a dose confirmation expected in first half of 2026; Confirmatory ASPENOVA Phase 3 trial initiation expected in first half of 2026; DENALI Part 2 topline readout on track and expected by year end 2026
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Zentalis Pharmaceuticals Announces Stock Repurchase Agreement
- Zentalis Pharmaceuticals Reports Q3 2025 Financial Results
- Zentalis price target lowered to $4 from $8 at Morgan Stanley
- Buy Rating for Zentalis Pharmaceuticals Driven by Promising Clinical Progress and Strategic Focus on PROC
- Zentalis reports Q3 EPS (37c), consensus (48c)